Genmab — Januar 2019
-
-
Syros also announced today that it has made a portfolio prioritization decision not to pursue further development of SY-1425 in combinationwith daratumumab beyond completion of the ongoing pilot cohort in the Phase 2 trial. https://www.marketwatch.com/press-release/syros-announces-strategic-priorities-and-expected-milestones-2019-01-06
-
Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs --> they still believe in BCMAxCD3 https://globenewswire.com/news-release/2019/01/07/1680967/0/en/Sanofi-and-Regeneron-Restructure-Immuno-Oncology-Collaboration-for-Discovery-and-Development-Programs.html#.XDMDpebNEr0.twitter
-
JNJ is on this afternoon at the JPM conference, could be a nice podium for a news release,
https://www.jnj.com/johnson-johnson-to-participate-in-37th-annual-jp-morgan-health-care-conference -
yes, good point @Sukkeralf , i would think they will, given that they stated exactly that in their business update (that they intend to actually combine their BCMA CD3 bispecific together with dara and not compete with dara)
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind